BC LAURUSLABS

Aditya Shyam Jalan
@Aditya_Jalan_3 3 years, 10 months ago 1203 views

#lauruslabs A perfect Volatility Contraction pattern on #Renko , Break above the zone of least resistance provides a low Risk - High Reward setup.
Targets around 800-885 open on PnF charts.
@Definedge
#nifty50 #Nse #StockMarket #stockstowatch

More from Aditya Shyam Jalan

@srvithal388 Sir, same thing happened with me, Stop was triggered bcoz of Intraday Move and I decided to enter again by taking the CR, but missed the bus.
Even though bus was missed , I feel delighted bcoz I followed the #process

#Deepakntr Super Pattern after a brief consolidation at ATH.
Count clusters till two decimal points.@srvithal388 @flyingvikas129 pic.twitter.com/5SFLEmz0Ia
— Aditya Shyam Jalan (@Aditya_Jalan_3) July 7, 2021

Aditya Shyam Jalan
@Aditya_Jalan_3

#hikal Undergoing a Volatility Contraction which can be appreciated in #Renko chart
#PnF next DTB gives a very favorable R:R entry
@Definedge
#NSE #StocksToBuy #StockMarket #stockstowatch #Nifty #trading

Aditya Shyam Jalan
@Aditya_Jalan_3

#Deepakntr Super Pattern after a brief consolidation at ATH.
Count clusters till two decimal points.
@srvithal388 @flyingvikas129

Aditya Shyam Jalan
@Aditya_Jalan_3

#Mahlog Undergoing a Volatility Contraction near its ATH area.
Probable ABC breakout and triangle formation in #PnF
@srvithal388 @flyingvikas129

Aditya Shyam Jalan
@Aditya_Jalan_3

Finally started moving 🌟 A VCP breakout
#Nifty #Happstmnds #Trading #PnF
It was also discussed in #ChitChart by @rajran06 sir.
@Definedge

#HAPPSTMNDS 1%
In line with the bullishness of the IT sector. Consolidated after a good upmove, providing a very low risk entry point .
CR entry at 1427
SL as the next probable Triple Bottom Sell at 1344.85#PnF #Trading #Process #StockMarket #StocksToWatch @Definedge pic.twitter.com/k76ViohZF2
— Aditya Shyam Jalan (@Aditya_Jalan_3) August 17, 2021

More from Lauruslabs

Rahul Singh Rajput
@nagusinghrajput

#POSITIONAL VIEW
#LAURUSLABS Spot (CMP - 661.60) Buy Above Day Close @675 for Target - 760/834/931 with STOP LOSS - 629 (DCB).

@Focus_SME @Jakerachoudhury

#Chart Enclosed.

$Tar \u26a1$

Tar ⚡
@itsTarH

📢 Announcement 📢

Every few days, I will post an infographic on some of the topics related to industries I am exploring.

Follow along and retweet to learn with me.

#LearnWithTar

Issue #1
What are Recombinant Proteins?

https://t.co/f8AE9aYqGF

#Laurusbio #RDNA

I now realize the typo with the spelling of Bacteria 😓

Here is a corrected version, if you want to download.

$TradingView India \U0001f1ee\U0001f1f3$

TradingView India 🇮🇳...
@in_tradingview

#LAURUSLABS - LAURUS LAB LONG - TradingView -

Man Vs Trade
@ManVsTrade

#MotilalOswal reiterated Buy Call on #lauruslabs with Target price of 800 means 23% upside from CMP. It's not just a noise or hype on Laurus. It's true that we will see laurus in a better position in 3 years. It's in a transforming phase. Try to accumulate in dips.

JST Investments
@JstInvestments

Laurus Labs FY21 Annual Report Takeaways 🔬

'Capex plans are already under way to increase capacity by 1.8x by 2022'

Hit the 'retweet' & help us educate more investors.

A Thread 🧵👇

1/ About the company:

Leadership position in generic APIs with a major focus on Antiretroviral drugs, Hepatitis C & Oncology drugs

FDF: Moved up the value chain in formulations

Synthesis (CDMO): KSMs, Intermediates & APIs to pharma innovators.

Bio: Recombinant products

2/ Strengths of the business:

Robust R&D & Process chemistry skills
Compliance that meets the most stringent regulatory expectations (USFDA, etc)
Long-standing relationships | Top 10 global pharma cos. catered

750+ scientists (R&D) | 61 DMFs | 27 ANDAs | 150 patents (292 filed)

3/ APIs: 54% of rev

- Leaders in various high-value & high-volume APIs.
- 4 high potent manufacturing facilities: 4186 KL, increasing capacity by 24% (Strong demand)
- ARV APIs were up 70% | Onco APIs up 25% | Other APIs up 56% (higher contract manufacturing orders from 🇪🇺)

4/ Formulations: 35% of rev

- Backwardly integrated: in house APIs
- Sales to LMIC, 🇺🇸 & 🇪🇺
- 27 ANDA filled: 9 approved+ 8 tentative.
- Capacity of 5 Billion units/yr, Increasing capacity by 100%
- Sales up 102% (growth across markets)
- Launched TLE 400 in the LMIC market

Next level tactic when closing a sale, candidate, or investment:

Ask: \u201cWhat needs to be true for you to be all in?\u201d

You'll usually get an explicit answer that you might not get otherwise. It also holds them accountable once the thing they need becomes true.
— Erik Torenberg (@eriktorenberg) February 27, 2018

2/ First, “X” could be lots of things. Examples: What would need to be true for you to

- “Feel it's in our best interest for me to be CMO"
- “Feel that we’re in a good place as a company”
- “Feel that we’re on the same page”
- “Feel that we both got what we wanted from this deal

3/ Normally, we aren’t that direct. Example from startup/VC land:

Founders leave VC meetings thinking that every VC will invest, but they rarely do.

Worse over, the founders don’t know what they need to do in order to be fundable.

4/ So why should you ask the magic Q?

To get clarity.

You want to know where you stand, and what it takes to get what you want in a way that also gets them what they want.

It also holds them (mentally) accountable once the thing they need becomes true.

5/ Staying in the context of soliciting investors, the question is “what would need to be true for you to want to invest (or partner with us on this journey, etc)?”

Multiple responses to this question are likely to deliver a positive result.

Jeet Heer
@HeerJeet

1. Now that Stan Lee is being eulogized far and wide, it's important to remember how marginal Stan Lee and his collaborators (Jack Kirby and Steve Ditko) were in the 1950s and 1960s.

2. Marvel Comics (before that Atlas) was just a cog in the machine of a bottom pulp publisher run by Martin Goodman, the husband of one of Lee's cousins. It was the lowest of the low in the publishing world.

3. Now Mario Puzo (not yet the author of the Godfather) shared offices with Stan Lee in the 1950s and 1960s. Puzo wrote for garrish men's adventure magazines and, like Lee, dreamed of writing a novel & breaking out. But Puzo looked down on Lee.

4. Flo Steinberg, 1960s secretary at Marvel: "They were always making jokes about us. They'd come in and giggle. mario Puzo would look in and would see us all working on his way to the office and say, 'Work faster, little elves. Christmas is coming.'"

5. When JFK was killed, the whole office of Magazine Management was stunned and quiet. Except Lee. He continued working. "He was still working on the comic books," Puzo said. "Like that was the most important thing in the world."

Anshul Pandey
@Anshulspiritual

STORY OF PURANAS AND SUB PURANA (उप पुराण).

We have already gone through the series on importance & characteristics of all the eighteen Purans. We also know that originally there were hundred crore shlokas but were divided by Vyas in each Kalp and was compiled as eighteen Purans

for the common people to understand it properly and now their total is about four lakhs.

In Brahm Puran, Brahma preached this to Marichi. So this Puran of ten thousand shlokas is called Brahm Puran.

In Padma Puran, the base of the story is the appearance of Brahma on a lotus(Padm) from Vishnu' s navel.This has fifty five thousand shlokas.

Vishnu Puran is primarily based in Varah kalp. This book is on Vishnu and this book has twenty three thousand shlokas.

Vaayu Puran is written in Shwet Kalp and has twenty four thousand shlokas. Here Vayudev preaches about Dharma.

In Bhagwat Puran, which is written with the base of Gayatri mantra describes Dharma extensively. It has 18000 shlokas. It also mentions the story of Vritrasur.

In Narad Puran, which has twenty five thousand shlokas, is a sermon on Dharma by Narad based in Brihad Kalp.

Markandeya Puran has nine thousand shlokas and here it is through the birds that Dharma is described.

$Billy Bostickson \U0001f3f4\U0001f441&\U0001f441 \U0001f193$

Billy Bostickson 🏴👁&👁 ...
@BillyBostickson

1. Project 1742 (EcoHealth/DTRA)
Risks of bat-borne zoonotic diseases in Western Asia

Duration: 24/10/2018-23 /10/2019

Funding: $71,500
@dgaytandzhieva
https://t.co/680CdD8uug

2. Bat Virus Database
Access to the database is limited only to those scientists participating in our ‘Bats and Coronaviruses’ project
Our intention is to eventually open up this database to the larger scientific community
https://t.co/mPn7b9HM48

3. EcoHealth Alliance & DTRA Asking for Trouble
One Health research project focused on characterizing bat diversity, bat coronavirus diversity and the risk of bat-borne zoonotic disease emergence in the region.
https://t.co/u6aUeWBGEN